10x Genomics Announces Pricing of Initial Public Offering
September 12 2019 - 7:00AM
10x Genomics, Inc. (“10x Genomics”) today announced the pricing of
its initial public offering of its Class A common stock at a price
of $39.00 per share, before underwriting discounts and commissions.
10x Genomics is offering 10,000,000 shares of its Class A common
stock, plus up to an additional 1,500,000 shares of its Class A
common stock that the underwriters have the right to purchase at
the initial public offering price, less the underwriting discounts
and commissions. The shares are expected to begin trading on the
Nasdaq Global Select Market on September 12, 2019 under the symbol
“TXG” and the offering is expected to close on September 16, 2019,
subject to the satisfaction of customary closing conditions.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and BofA
Merrill Lynch are acting as lead joint book-running managers for
the offering. Cowen is acting as lead manager for the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission, and became
effective on September 11, 2019. This offering is being made only
by means of a prospectus, copies of which may be obtained from:
J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by
telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New
York, New York 10282, by telephone at (866) 471-2526, or by email
at prospectus-ny@ny.email.gs.com; or BofA Merrill Lynch,
NC1-004-03-43; 200 North College Street, 3rd floor,
Charlotte, North Carolina 28255-0001, Attention: Prospectus
Department, or by email
at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contacts:
Investorsinvestors@10xgenomics.com
Mediamedia@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Sep 2023 to Sep 2024